The companies anticipate finalising the acquisition in the third quarter of 2026.
The acquisition aligns with Servier’s strategic goal in rare neurology. Credit: Vernerie Yann / Shutterstock.com.
Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.
The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
